donation
To request Mental Health
Services or to access Mental
Health Crisis Services Call:
1-800-375-4357

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Almost 13 Million Americans Per Year Skip Meds Due to CostAssistance Dogs Bring Big Boost to Deaf PeopleCDC to Toughen COVID Testing for International TravelersOld Spice, Secret Antiperspirants Recalled Due to BenzeneClinical Trials Are Becoming More Diverse, But There's Still Work To DoRural Hospitals' ERs Just as Effective as Urban Ones: StudyKraft Recalls Powdered Drinks Over Metal, Glass ConcernsVials Found in Lab Contained Vaccine, not Smallpox Virus: CDCAdvances in Care, Impact of COVID Highlights of Latest Cardiologists' MeetingAcross America, Black People Have Worse Health OutcomesVials With Smallpox Labels Found at Vaccine Lab in Pennsylvania: CDCWhite House to Spend Billions to Boost COVID Vaccine SupplyAHA News: Health Class May Influence Heart Risk in South AsiansPfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor CountriesFederal Court Backs Stay on COVID Vaccine Mandate for Large BusinessesMore Than 2 Million COVID Home Test Kits Recalled Due to False Positive ResultsIn Canada, Ban on Menthol Cigarettes Had More Smokers QuittingOklahoma Supreme Courts Overturns $465 Million J & J Opioid RulingPandemic Puts 'Outdated' Infection Control Practices Under ScrutinyMillions of Tons of COVID Masks, Gloves Will End Up in OceansSales of Unproven, Unapproved Stem Cell Therapies Are BoomingCourt Temporarily Blocks Biden’s Vaccine Mandate for Big BusinessesU.S. Reopens Borders to Vaccinated Foreign TravelersIt's Time to Replace Your Smoke Alarm BatteriesAHA News: How Doctors Can Help Their Patients Make Heart-Healthy Lifestyle ChangesWhite House Sets Jan. 4 Deadline for Large, Private U.S. Companies to Mandate VaccinesHepatitis B Shots Advised for All U.S. Adults Under 60Supply Chain Issues Bring Shortages of Drugs, Devices to U.S. HospitalsMedicare Could Negotiate Drug Prices Under Democrat ProposalWe've Been Here Before: How Polio Vaccine Rollout Saved Millions of Young LivesAlmost 1 in 3 U.S. Seniors Now Sees at Least 5 Doctors Per YearLanguage Can Make the Difference Between Home, Hospital Care: StudyAttorneys General Warn About Pot Products That Look Like Halloween TreatsCDC Lowers Threshold for Lead Poisoning in Youngest KidsStronger Breast Implant Safety Measures Announced by FDAWalmart Recalls Room Spray for Rare Bacteria That Sickened 4, Killing 2U.S. Gun Violence Rates Jumped 30% During PandemicMandates, Not Recommendations, Work Best to Get Folks Vaccinated: StudyU.S. Has Shared 200 Million Shots With Other CountriesLittle Change Seen in Americans' Use of Mental Health Services During PandemicWomen Doctors Face Higher Levels of Harassment, Frustration: SurveyEPA Plans New Strategy Against PFAS 'Forever Chemicals'State Spending on Poverty Really Pays Off for Kids: StudyState Lotteries Didn't Help Boost Vaccination RatesVaccinated Foreign Travelers Can Enter United States Beginning Nov. 8Despite Pressures of Pandemic, U.S. Nursing School Enrollment ClimbsBiden Administration to Invest $100 Million to Ease Health Worker ShortageFDA Warns Against Using At-Home Dermal Filler 'Pens'Death Threats, Trolling Common for Scientists Who Speak to Media About COVID'Extreme Heat' Days Have Tripled Since 1980s, and More Are Coming
Questions and AnswersLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Nearly 200,000 COVID Home Tests Recalled Over False Positives

HealthDay News
by Robert Preidt and Robin Foster
Updated: Oct 6th 2021

new article illustration

WEDNESDAY, Oct. 6, 2021 (HealthDay News) -- Almost 200,000 Ellume COVID-19 home testing kits have been recalled because they may be more likely to give a false positive result.

The problem with the rapid antigen tests was identified in mid-September and caused by variations in the quality of one of the raw materials used in the products, Ellume CEO Dr. Sean Parsons told The New York Times.

The Ellume test kits received emergency use authorization from the U.S. Food and Drug Administration last December, and the Australian company had already shipped about 3.5 million of the test kits to this country.

About 427,000 of those kits were affected by the problem, and about half have already been used, returning about 42,000 positive results, Parsons told the Times.

He said it would be difficult to determine how many of those positive results may have been incorrect, but said the rate could be as high as one quarter.

The issue with the recalled test kits doesn't affect the reliability of negative results, according to the company.

Ellume's test is designed to detect pieces of the virus in the nose. After swabbing the nostrils, the swab is inserted into a dropper of fluid, and the fluid is then added to a Bluetooth-connected analyzer. Results arrive via a smart phone app in 15 minutes.

The company said it has asked retailers to stop selling the recalled kits and has notified consumers about the issue.

Consumers should go to the Ellume website to see if their home test kit is included in the recall and to get instructions on what to do if it is, the company said.

To arrange a replacement, consumers can call Ellume at 1-888-807-1501, 9 a.m. to 5 p.m. ET, Monday through Friday.

People who try to use one of the affected test kits will be notified in the app that the test has been recalled, Parsons explained. "It really won't be possible to use any of those tests now," he added.

He noted that the company had put "extra controls" in place to prevent the same problem from happening again in the future.

"I'm very sorry that this has happened," Parsons told the Times. "We're all about chasing accuracy, and to have these false positives is disappointing."

The recall comes as demand for at-home testing has soared, and consumers have complained that test kits are hard to find, the Times reported.

On Monday, a new at-home antigen test from ACON Laboratories was approved for emergency use by the FDA.

That approval "is expected to double rapid at-home testing capacity in the U.S. over the next several weeks," Dr. Jeffrey Shuren, who directs the FDA's Center for Devices and Radiological Health, said in a statement. "By year's end, the manufacturer plans to produce more than 100 million tests per month, and this number will rise to 200 million per month by February 2022."

"Since March 2020, the FDA has authorized more than 400 COVID-19 tests and sample collection devices, including authorizations for rapid, OTC at-home tests," Shuren added. "The FDA considers at-home COVID-19 diagnostic tests to be a high priority and we have continued to prioritize their review given their public health importance."

More information

Visit the U.S. Centers for Disease Control and Prevention for more on COVID testing.


SOURCE: The New York Times; Oct. 5, 2021 statement, U.S. Food and Drug Administration